Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome
- PMID: 26500878
- PMCID: PMC4594407
- DOI: 10.4103/2229-5178.164488
Liposomal doxorubicin-induced palmoplantar erythrodysthesia syndrome
Figures
References
-
- Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (“hand–foot”) syndrome: Incidence, recognition and management. Am J Clin Dermatol. 2000;1:225–34. - PubMed
-
- Gressett SM, Stanford BL, Hardwicke F. Management of hand–foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12:131–41. - PubMed
-
- Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984;101:798–9. - PubMed
-
- Doyle LA, Berg C, Bottino G, Chabner B. Erythema and desquamation after high-dose methotrexate. Ann Intern Med. 1983;98:611–2. - PubMed
-
- Cox GJ, Robertson DB. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol. 1986;122:1413–4. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources